On January 20, 2026, the U.S. Food and Drug Administration awarded Breakthrough Therapy status to Eli Lilly’s investigational topoisomerase I inhibitor, sofetabart mipitecan, for the treatment of adults with platinum-resistant ovarian cancer who have received at least two prior systemic therapies. The designation follows interim data from a Phase 2 trial in which 38% of evaluable patients achieved objective tumor responses and median progression-free survival extended to 5.4 months, compared with historical controls of approximately 3.5 months. Breakthrough status will allow Lilly to work closely with FDA on expedited development and review processes, potentially shortening the path to a New Drug Application later this year. Lilly expects to initiate a randomized Phase 3 comparison against physician’s choice chemotherapy by mid-2026, enrolling up to 500 patients across North America and Europe.

Eli Lilly will release its fourth-quarter 2025 financial results on February 4, 2026, at 7:30 a.m. Eastern, followed by a live conference call at 10:00 a.m. Eastern. Management will review full-year sales growth, which analysts project to exceed 20% driven by strength in GLP-1 products, and provide first public commentary on gross margin expansion initiatives targeting a 200-basis-point improvement in 2026. The call will also cover R&D investment, including planned Phase 3 starts in Alzheimer’s and cardiovascular indications, and updated guidance on capital allocation—with share repurchases expected to reach $6 billion and dividends poised to rise by mid-single digits. Live and replay webcasts will be accessible via Lilly’s investors website.

Beyond ovarian cancer and quarterly results, Lilly continues to leverage its nearly 150-year heritage in biotechnology and chemistry to fuel a rich late-stage pipeline. The company has six additional Phase 3 trials slated to read out in 2026, including two for Alzheimer’s disease and one for a next-generation diabetes therapy. Management reiterated its long-term goal of sustaining double-digit adjusted EPS growth through 2030, supported by planned launches in oncology, neurodegeneration and obesity. Institutional investors currently allocate over 30% of Lilly’s free cash flow to R&D, underscoring the company’s commitment to innovation while maintaining a strong investment-grade balance sheet with net debt below 1.5x EBITDA.